Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
0.7091
+0.0038 (+0.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bluebird Bio
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
March 18, 2024
From
bluebird bio, Inc.
Via
Business Wire
Is Bluebird Bio Stock a Buy Now?
March 13, 2024
Are you feeling brave?
Via
The Motley Fool
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
March 11, 2024
From
bluebird bio, Inc.
Via
Business Wire
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
March 06, 2024
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
Via
MarketBeat
Forecasting The Future: 6 Analyst Projections For bluebird bio
March 05, 2024
Via
Benzinga
(BLUE) - Analyzing bluebird bio's Short Interest
February 29, 2024
Via
Benzinga
Why Bluebird Bio Stock Dived Into the Red on Tuesday
March 05, 2024
The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation.
Via
The Motley Fool
MarketBeat Week in Review – 2/26 - 3/1
March 02, 2024
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
bluebird bio Stock Signals Potential to be a Multi-bagger
February 29, 2024
Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could do
Via
MarketBeat
Topics
Economy
Exposures
Economy
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
February 27, 2024
Both companies are working on treatments for genetic disorders.
Via
Investor's Business Daily
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 29, 2024
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
Via
Benzinga
bluebird bio: How to play LEAPS options for growth and income
February 27, 2024
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT
Via
MarketBeat
Exposures
Product Safety
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via
Benzinga
bluebird bio stock is ripe for a 400% institutional short squeeze
February 27, 2024
Bluebird Bio stock could be on the verge of a 400% pop on earnings, management has set the writing on the wall for institutional buying to trickle in
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Is CRISPR Therapeutics the NVIDIA of gene editing?
February 26, 2024
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
Exposures
Product Safety
If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today
January 27, 2024
The answer hardly inspires confidence.
Via
The Motley Fool
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
January 17, 2024
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the...
Via
Benzinga
Exposures
Product Safety
2 Red Flags for Bluebird Bio Stock
January 10, 2024
The biotech's struggles may continue.
Via
The Motley Fool
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
January 08, 2024
From
bluebird bio, Inc.
Via
Business Wire
Better Risky Investment: Bluebird Bio vs. Shiba Inu
January 03, 2024
Few investors dare to tread where the ice is known to be very thin.
Via
The Motley Fool
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
bluebird bio, Inc.
Via
Business Wire
Should You Invest in Bluebird Bio Right Now?
December 26, 2023
After two December share price crashes, there's no evident cure for Bluebird Bio's ills.
Via
The Motley Fool
If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today
December 24, 2023
Can things get better for this struggling stock?
Via
The Motley Fool
1 Green Flag and 1 Red Flag for Bluebird Bio Stock
December 23, 2023
The stock has been in the news lately.
Via
The Motley Fool
3 Money-Saving Tricks for Investing in Biotech Stocks in 2024
December 22, 2023
Doing a little math and doing a little extra research can make a big difference.
Via
The Motley Fool
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
December 22, 2023
The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.
Via
The Motley Fool
Exposures
Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 21, 2023
Via
Benzinga
S&P 500 Edges Lower; General Mills Cuts Sales Forecast
December 20, 2023
U.S. stocks traded mixed toward the end of trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.07% to 37,586.02 while the NASDAQ rose 0.17% to 15,029.36. The S&P 500, however,...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.